Abivax SA Overview
Pro stress-test →Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Obefazimod, Abivax's lead drug candidate, is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response.
Strategic Profile
Pro stress-test →In August 2025, the stock price of Abivax surged by around 580% following dual Phase III success in ulcerative colitis. Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate. The company is positioned as a potential market leader in inflammatory bowel disease treatment with a novel mechanism of action.
Competitive Landscape
Pro stress-test →Competitors include Transgene, Regeneron Pharmaceuticals, Astellas Pharma, and Galectin Therapeutics. Abivax differentiates through its first-in-class miR-124 enhancement mechanism versus existing JAK inhibitors and S1P modulators in the IBD space.
Industry Context
Abivax SA operates in Biotechnology / Pharmaceutical.
Key facts
Founded: 2013 · Headquarters: Paris, France · Employees: 69 · Revenue: $10.79M · Market cap: $9.9B